202646-80-8

Basic information

• Product Name: 2-(1-Methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-one
• Synonyms: FR-194921
• CAS NO: 202646-80-8
• Molecular Formula: C₂₃H₂₃N₅O
• Molecular Weight: 385.47266
• Mol File: 202646-80-8.mol

Chemical Properties

• CAS DataBase Reference: 2-(1-Methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-Methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-one(202646-80-8)
• EPA Substance Registry System: 2-(1-Methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-one(202646-80-8)

Safety Data

• Hazardous Substances Data: 202646-80-8(Hazardous Substances Data)

Usage

Chemical structure

Contains a piperidinyl group, a pyridinyl group, and a pyrazolopyridinyl group.

Type of compound

Pyridazinone derivative.

Potential properties

Has potential pharmacological properties.

Interest in research

May be of interest for further research and development in the field of medicinal chemistry.

Potential use

Could potentially be a candidate for drug discovery and development due to its unique and intricate chemical structure.

Biological and pharmacological activities

Not well-documented, requiring further studies to understand its potential impact and applications.

Upstream product

• 106-52-5 N-methyl-4-hydroxypiperidine 
• 131185-06-3 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo<1,5-a>pyridine 
• 1972-28-7 diethylazodicarboxylate 
• 5382-23-0 4-chloro-N-methyl-piperidine hydrochloride 

Relevant articles and documents

Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability

A novel series of 3-(2-substituted-3-oxo-2,3-dihydropyridazin-6-yl) -2-phenylpyrazolo[1,5-a]pyridines (5-38) were synthesized and evaluated for their in vitro adenosine A1 and A2A receptor binding activities, and in vitro metabolism by rat liver in order to search for orally active compounds. Most of the test compounds were potent adenosine A1 receptor antagonists with high A1 selectivity and the A1 affinity and A1 selectivity of carbonyl derivatives (5-11) was particularly high. In particular, compound 7 was an extremely potent and selective adenosine A1 antagonist with high A1 selectivity (Ki=0.026 nM, A2A/A1=5400). In terms of metabolic stability, 2-oxopropyl (5), 2-hydroxypropyl (12), N-methylacetamide (16), 2-(piperidin-1-yl)ethyl (28) and 1-methylpiperidin-4-yl (32, FR194921) were the most stable compounds in this series of analogues. Further in vivo evaluation indicated that compounds 5, 13, 17, 28 and 32 were detected in both plasma and brain after oral administration in rats. In particular, 32 displayed good plasma and brain concentrations (dose: 32mg/kg (n=3); after 30 min, plasma conc.=3390±651 nM, brain conc.=3670±496 nM; after 60 min, plasma conc.=1580±348 nM, brain conc.=2143±434 nM), and a good brain/plasma ratio (1.11±0.060 (30 min), 1.39±0.172 (60 min)). As a result, we could show that 32 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6 nM, A2A/A1=820, BA=60.6±4.9% (32 mg/kg)).

Pyrazolopyridine compound and pharmaceutical use thereof

PCT No. PCT/JP97/02493 Sec. 371 Date Jan. 19, 1999 Sec. 102(e) Date Jan. 19, 1999 PCT Filed Jul. 17, 1997 PCT Pub. No. WO98/03507 PCT Pub. Date Jan. 29, 1998A pyrazolopyridine compound of formula (I) wherein R1 is aryl, and R2 is lower alkyl substituted w